| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 1066.67% | Raymond James | $18.5 → $17.5 | Maintains | Outperform |
| 08/15/2023 | 1233.33% | Baird | $30 → $20 | Maintains | Outperform |
| 08/15/2023 | 366.67% | HC Wainwright & Co. | $2.5 → $7 | Maintains | Buy |
| 07/13/2023 | 1133.33% | Raymond James | $17 → $18.5 | Maintains | Outperform |
| 06/23/2023 | 1033.33% | Raymond James | $20 → $17 | Maintains | Outperform |
| 05/16/2023 | 66.67% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 04/13/2023 | 33.33% | Mizuho | → $2 | Reiterates | → Buy |
| 03/27/2023 | 66.67% | HC Wainwright & Co. | → $2.5 | Reiterates | → Buy |
| 03/27/2023 | 33.33% | Raymond James | $2.5 → $2 | Maintains | Outperform |
| 03/17/2023 | 33.33% | Mizuho | $3 → $2 | Maintains | Buy |
| 01/27/2023 | 100% | Mizuho | $6 → $3 | Maintains | Buy |
| 01/18/2023 | 66.67% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
| 11/11/2022 | 66.67% | Raymond James | $3.5 → $2.5 | Maintains | Outperform |
| 08/15/2022 | 133.33% | Raymond James | $3 → $3.5 | Maintains | Outperform |
| 07/13/2022 | 100% | Raymond James | $4 → $3 | Maintains | Outperform |
| 10/04/2021 | 300% | Mizuho | → $6 | Initiates Coverage On | → Buy |
| 09/14/2021 | 166.67% | Raymond James | $3 → $4 | Maintains | Outperform |
| 03/02/2021 | 133.33% | Raymond James | $2.5 → $3.5 | Maintains | Outperform |
| 08/17/2020 | 166.67% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 06/29/2020 | 300% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 05/19/2020 | 233.33% | HC Wainwright & Co. | $2.5 → $5 | Reiterates | → Buy |
| 03/17/2020 | 66.67% | HC Wainwright & Co. | $3.25 → $2.5 | Maintains | Buy |
| 02/11/2020 | 300% | Baird | → $6 | Initiates Coverage On | → Outperform |
| 01/08/2020 | 66.67% | Raymond James | → $2.5 | Upgrades | Market Perform → Outperform |
| 11/15/2019 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 12/19/2018 | 433.33% | Raymond James | $13 → $8 | Maintains | Outperform |
What is the target price for Leap Therapeutics (LPTX)?
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Raymond James on November 14, 2023. The analyst firm set a price target for $17.50 expecting LPTX to rise to within 12 months (a possible 1066.67% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Leap Therapeutics (LPTX)?
The latest analyst rating for Leap Therapeutics (NASDAQ: LPTX) was provided by Raymond James, and Leap Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Leap Therapeutics (LPTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Leap Therapeutics (LPTX) correct?
While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a maintained with a price target of $18.50 to $17.50. The current price Leap Therapeutics (LPTX) is trading at is $1.50, which is out of the analyst's predicted range.